Table 1.

Baseline demographics, clinical and laboratory characteristics of study cohort.

	Dmab group (n = 13)	ZOL group (n = 10)	Controls (n = 14)
Age (years)	58.31 ± 9.77	54.10 ± 13.88	50.29 ± 6.59
BMI (kg/m2)	24.61 ± 4.82	23.33 ± 3.49	25.46 ± 2.67
ART duration (years)	9.96 ± 5.86	10.75 ± 7.19	9.00 ± 6.40
TDF use [n(%)]	10(76.9%)	8(80%)	9(65%)
TDF duration (years)	7.25 ± 5.14	6.60 ± 7.55	7.07 ± 7.29
NRTIs duration (years)	9.27 ± 6.31	10.75 ± 7.19	9.00 ± 6.41
NNRTIs duration (years)	3.40 ± 5.43	3.30 ± 6.14	2.01 ± 3.28
PIs duration (years)	5.04 ± 3.16a	7.25 ± 6.8.47a	1.14 ± 4.28
PINP (ng/mL)	40.94 ± 28.46	47.82 ± 28.21	49.41 ± 16.56
CTX (ng/mL)	0.35 ± 0.38	0.42 ± 0.26	0.37 ± 0.15
Urea (mg/dL)	36.23 ± 10.81	36.30 ± 12.21	35.86 ± 18.75
Creatinine (mg/dL)	1.06 ± 0.18	0.95 ± 0.12	1.01 ± 0.16
Calcium (mg/dL)d	9.16 ± 0.38	9.12 ± 0.54	9.03 ± 0.32
Phosphate (mg/dL)	2.91 ± 0.49	3.13 ± 0.28	3.12 ± 0.66
ALP	92.23 ± 22.19	86.50 ± 15.59	86.71 ± 27.26
25(OH)D (nmol/L)	40.12 ± 9.6	70.61 ± 37.69b	77.24 ± 36.13c

Parameters did not differ significantly between groups with the exception of those indicated.

Dmab,Denosumab; ZOL, Zoledronate; BMI, body mass índex; ART, anti-retroviral treament; NRTIs, nucleoside analog reverse-transcriptase inhibitors; TDF, tenoforvir; NNRTIs, non-nucleoside analog reverse-transcriptase inhibitors; PIs, protease inhibitors; P1NP, procollagen type 1 amino-terminal CTX, carboxy-terminal telopeptide cross-linked type 1 collagen ALP, alkaline phosphatase.

^ap < 0.001 vs. Controls.

^bp = 0.007 vs. Dmab group.

^cp < 0.001 vs. Dmab group.

^dCorrected for albumin.